These trials and others are ongoing (Table 1) but the preliminary conclusion is that these drugs will be tolerated, although QTc monitoring will be important, and they potentially have single agent activity in patients with MLL-rearranged or NPM1 mutant AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.